论文部分内容阅读
目的对比缬沙坦与贝那普利治疗原发性高血压的临床效果。方法选择医院2014年3月-2016年2月收治的原发性高血压患者100例,根据随机抽样原则分为试验组与对照组各50例,试验组采用缬沙坦治疗,对照组采用贝那普利治疗,比较2组患者的治疗效果和不良反应。结果治疗前2组收缩压、舒张压比较差异无统计学意义(P>0.05);治疗后2组收缩压、舒张压均下降,且试验组低于对照组,差异均有统计学意义(P<0.05)。试验组总有效率为98.00%高于对照组的88.00%,差异有统计学意义(P<0.05)。试验组不良反应发生率为4.0%,对照组为14.0%,2组比较差异无统计学意义(P>0.05)。结论缬沙坦治疗原发性高血压患者疗效优于贝那普利,且不良反应相对较小,值得临床推广应用。
Objective To compare the clinical effects of valsartan and benazepril in the treatment of essential hypertension. Methods One hundred patients with essential hypertension were selected from March 2014 to February 2016 in our hospital. According to the principle of random sampling, 50 cases were divided into trial group and control group. The treatment group was treated with valsartan, while the control group was treated with Treatment with nalapix, the treatment effect and adverse reactions in two groups were compared. Results There was no significant difference in systolic blood pressure and diastolic blood pressure between the two groups before treatment (P> 0.05). Systolic blood pressure and diastolic blood pressure were decreased in both groups after treatment, and the difference between the two groups was statistically significant (P <0.05). The total effective rate of the experimental group was 98.00% higher than that of the control group (88.00%), the difference was statistically significant (P <0.05). The incidence of adverse reactions was 4.0% in the experimental group and 14.0% in the control group. There was no significant difference between the two groups (P> 0.05). Conclusion Valsartan is superior to benazepril in the treatment of patients with essential hypertension, and the adverse reactions are relatively small, worthy of clinical application.